Neurologists Warn GLP-1 Drugs Triggered 10-Fold ALS Decline After 25-Pound Weight Loss
Updated
Updated · Fox News · Jul 16
Neurologists Warn GLP-1 Drugs Triggered 10-Fold ALS Decline After 25-Pound Weight Loss
2 articles · Updated · Fox News · Jul 16
Summary
A 2025 case report found a 52-year-old ALS patient’s physical deterioration accelerated 10-fold after starting semaglutide, alongside a 25-pound weight loss in three months.
Neurologists say that pattern fits ALS biology: patients often need to maintain or even gain weight, because caloric deficit and hypermetabolism can speed nerve and muscle decline.
Jinsy Andrews of NYU Langone said GLP-1 drugs may worsen ALS whether or not a patient has diabetes, even though the medicines broadly help obesity, cardiovascular risk, liver disease and addiction.
The patient’s rapid decline stabilized after semaglutide was stopped, and Andrews said that case plus retrospective data in ALS patients with diabetes supports much greater prescribing caution in neurodegenerative disease.
Beyond shedding pounds, are GLP-1s causing silent, long-term harm to muscles and nerves?
Are popular weight-loss drugs accelerating fatal neurodegenerative diseases?
GLP-1 Receptor Agonists Linked to Faster ALS Progression: Critical Risks and Clinical Guidance
Overview
This report highlights an urgent warning from July 2026, where a neurologist advised extreme caution when using GLP-1 receptor agonists in patients with ALS and other neurodegenerative diseases. The warning is based on growing concerns that these drugs, commonly used for diabetes and obesity, may accelerate ALS progression. Supporting this, recent research has linked GLP-1 drugs to negative neurological outcomes, prompting the medical community to reconsider their use in vulnerable patients. The report emphasizes the need for healthcare providers to carefully weigh the risks and benefits, as maintaining weight is crucial for ALS patients, and GLP-1 drugs promote weight loss.